Popova, N F, Kamchatnov, P R, Riabukhina, O V et al. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2010
This study tested a combination medication called omaron in 33 patients with multiple sclerosis to see if it could help with fatigue and thinking problems. After 12 weeks of treatment, patients taking omaron reported feeling less tired (28.6% improvement) and showed better memory and thinking skills compared to a similar group who didn't receive the medication. The drug was well-tolerated with no serious side effects.
Fatigue and cognitive dysfunction are prominent features of both MS and ME/CFS, making treatments targeting these symptoms potentially relevant to both conditions. This study suggests that nootropic combinations may offer symptomatic benefit for chronic fatigue and cognitive impairment, which could inform investigation of similar approaches in ME/CFS populations.
This study does not establish that omaron is effective for ME/CFS specifically, as it examined only MS patients. The observational design without randomization or blinding cannot prove the medication caused the improvements—they could reflect placebo effect, natural disease fluctuation, or other unmeasured factors. The small sample size and lack of baseline fatigue severity stratification limit generalizability.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.